ELISA/assay

Mouse Very low density lipoprotein receptor ELISA Kit

MBS721361

48-Strip-Wells

470 USD

ELISA Kit

Mouse Very low density lipoprotein receptor ELISA Kit

Very low density lipoprotein receptor

very low-density lipoprotein receptor isoform a; Very low-density lipoprotein receptor; very low-density lipoprotein receptor; VLDL-R; VLDL receptor; very low density lipoprotein receptor

VLDLR

VLDLR; VLDLR; CARMQ1; CHRMQ1; VLDLRCH; VLDL receptor; VLDL-R

VLDLR_HUMAN

Mouse

This assay has high sensitivity and excellent specificity for detection of VLDLR. No significant cross-reactivity or interference between VLDLR and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between VLDLR and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C.

Samples: Serum, plasma, Cell Culture Supernatants, body fluid and tissue homogenate. Assay Type: Competitive. Sensitivity: 0.1 ng/mL.

Intended Uses: This VLDLR ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Mouse VLDLR. This ELISA kit for research use only, not for therapeutic or diagnostic applications!

Cardiovascular

Principle of the assay: VLDLR ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-VLDLR antibody and an VLDLR-HRP conjugate. The assay sample and buffer are incubated together with VLDLR-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the VLDLR concentration since VLDLR from samples and VLDLR-HRP conjugate compete for the anti-VLDLR antibody binding site. Since the number of sites is limited, as more sites are occupied by VLDLR from the sample, fewer sites are left to bind VLDLR-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The VLDLR concentration in each sample is interpolated from this standard curve.

65301167

NP_003374.3

NM_003383.3

93,383 Da

Lissencephaly Gene (LIS1) In Neuronal Migration And Development Pathway (137984); Reelin Signaling Pathway (137980)

The low density lipoprotein receptor (LDLR) gene family consists of cell surface proteins involved in receptor-mediated endocytosis of specific ligands. This gene encodes a lipoprotein receptor that is a member of the LDLR family and plays important roles in VLDL-triglyceride metabolism and the reelin signaling pathway. Mutations in this gene cause VLDLR-associated cerebellar hypoplasia. Alternative splicing generates multiple transcript variants encoding distinct isoforms for this gene. [provided by RefSeq, Aug 2009]

VLDLR: Binds VLDL and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. Binding to Reelin induces tyrosine phosphorylation of Dab1 and modulation of Tau phosphorylation. Defects in VLDLR are the cause of cerebellar ataxia mental retardation and dysequilibrium syndrome type 1 (CMARQ1); also known as dysequilibrium syndrome (DES) or non- progressive cerebellar disorder with mental retardation. CMARQ1 is a congenital, non-progressive cerebellar ataxia associated with disturbed equilibrium, delayed ambulation, mental retardation and cerebellar hypoplasia. Additional features include short stature, strabismus, pes planus and, rarely, seizures. 2 isoforms of the human protein are produced by alternative splicing. Protein type: Receptor, misc.; Membrane protein, integral. Chromosomal Location of Human Ortholog: 9p24. Cellular Component: membrane; integral to membrane; plasma membrane; coated pit; receptor complex. Molecular Function: very-low-density lipoprotein receptor activity; low-density lipoprotein receptor activity; very-low-density lipoprotein binding; protein binding; apolipoprotein binding; calcium ion binding; glycoprotein binding; calcium-dependent protein binding. Biological Process: receptor-mediated endocytosis; nervous system development; cholesterol metabolic process; positive regulation of protein kinase activity; ventral spinal cord development; negative regulation of transcription from RNA polymerase II promoter; lipid transport; signal transduction; memory. Disease: Cerebellar Ataxia, Mental Retardation, And Dysequilibrium Syndrome 1

48-Strip-Wells

470 USD

96-Strip-Wells

675